Latest & greatest articles for chronic kidney disease

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on chronic kidney disease or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on chronic kidney disease and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for chronic kidney disease

41. Multiple-frequency bioimpedance devices for fluid management in people with chronic kidney disease receiving dialysis: a systematic review and economic evaluation

Multiple-frequency bioimpedance devices for fluid management in people with chronic kidney disease receiving dialysis: a systematic review and economic evaluation Multiple-frequency bioimpedance devices for fluid management in people with chronic kidney disease receiving dialysis: a systematic review and economic evaluation Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could (...) not be found. Please choose a page from the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> {{metadata.Title}} {{metadata.Headline}} Overhydration is significantly lower among people with chronic kidney disease having dialysis who are managed using the BCM-Body Composition Monitor, but the probability that bioimpedance monitoring is cost-effective at a threshold of £20,000 per QALY is very uncertain. {{author}} {{($index

NIHR HTA programme2018

42. Whole-Exome Sequencing in Adults With Chronic Kidney Disease: A Pilot Study.

Whole-Exome Sequencing in Adults With Chronic Kidney Disease: A Pilot Study. Background: The utility of whole-exome sequencing (WES) for the diagnosis and management of adult-onset constitutional disorders has not been adequately studied. Genetic diagnostics may be advantageous in adults with chronic kidney disease (CKD), in whom the cause of kidney failure often remains unknown. Objective: To study the diagnostic utility of WES in a selected referral population of adults with CKD. Design (...) with tubulointerstitial fibrosis. PARN mutations have been implicated in a short telomere syndrome characterized by lung, bone marrow, and liver fibrosis; these findings extend the phenotype of PARN mutations to renal fibrosis. In addition, review of the American College of Medical Genetics actionable genes identified a pathogenic BRCA2 mutation in a proband who was diagnosed with breast cancer on follow-up. The results affected clinical management in most solved cases, including initiation of targeted surveillance

Annals of Internal Medicine2017

43. Derivation and External Validation of Prediction Models for Advanced Chronic Kidney Disease Following Acute Kidney Injury.

Derivation and External Validation of Prediction Models for Advanced Chronic Kidney Disease Following Acute Kidney Injury. Importance: Some patients will develop chronic kidney disease after a hospitalization with acute kidney injury; however, no risk-prediction tools have been developed to identify high-risk patients requiring follow-up. Objective: To derive and validate predictive models for progression of acute kidney injury to advanced chronic kidney disease. Design, Setting (...) 2004-March 2014, with follow-up to March 2015). The risk models were externally validated with data from a cohort of 2761 patients hospitalized in Ontario, Canada (June 2004-March 2012, with follow-up to March 2013). Exposures: Demographic, laboratory, and comorbidity variables measured prior to discharge. Main Outcomes and Measures: Advanced chronic kidney disease was defined by a sustained reduction in eGFR less than 30 mL/min/1.73 m2 for at least 3 months during the year after discharge. All

JAMA2017

44. Effect of Sertraline on Depressive Symptoms in Patients With Chronic Kidney Disease Without Dialysis Dependence: The CAST Randomized Clinical Trial.

Effect of Sertraline on Depressive Symptoms in Patients With Chronic Kidney Disease Without Dialysis Dependence: The CAST Randomized Clinical Trial. Importance: Major depressive disorder (MDD) is prevalent among patients with chronic kidney disease (CKD) and is associated with morbidity and mortality. The efficacy and adverse events of selective serotonin reuptake inhibitors in these patients are unknown. Objective: To determine whether treatment with sertraline improves depressive symptoms (...) in patients with CKD and MDD. Design, Setting, and Participants: The Chronic Kidney Disease Antidepressant Sertraline Trial (CAST) was a randomized, double-blind, placebo-controlled trial involving 201 patients with stage 3, 4, or 5 non-dialysis-dependent CKD, who were enrolled at 3 US medical centers. The Mini Neuropsychiatric Interview was used to establish MDD. The first participant was randomized in March 2010 and the last clinic visit occurred in November 2016. Interventions: After a 1-week placebo

JAMA2017

45. Uric acid lowering therapies for preventing or delaying the progression of chronic kidney disease.

Uric acid lowering therapies for preventing or delaying the progression of chronic kidney disease. BACKGROUND: Non-randomised data have shown a link between hyperuricaemia and the progression or development of chronic kidney disease (CKD). If this is correct, urate lowering therapy might form an important part of chronic kidney disease care, reducing risks for cardiovascular outcomes and end-stage kidney disease. OBJECTIVES: This review aims to study the benefits and harms of uric acid lowering (...) kidney disease but the conclusion is very uncertain. Benefits were not observed at all time points and study quality was generally low. Larger studies are required to study the effect of uric acid lowering therapy on CKD progression. Three ongoing studies will hopefully provide much needed high quality data.

Cochrane2017

46. Do attributes of persons with chronic kidney disease differ in low-income and middle-income countries compared with high-income countries? Evidence from population-based data in six countries

Do attributes of persons with chronic kidney disease differ in low-income and middle-income countries compared with high-income countries? Evidence from population-based data in six countries 29071132 2018 11 13 2059-7908 2 4 2017 BMJ global health BMJ Glob Health Do attributes of persons with chronic kidney disease differ in low-income and middle-income countries compared with high-income countries? Evidence from population-based data in six countries. e000453 10.1136/bmjgh-2017-000453 Kidney (...) biopsies to elucidate the cause of chronic kidney disease (CKD) are performed in a minority of persons with CKD living in high-income countries, since associated conditions-that is, diabetes mellitus, vascular disease or obesity with pre-diabetes, prehypertension or dyslipidaemia-can inform management targeted at slowing CKD progression in a majority. However, attributes of CKD may differ substantially among persons living in low-income and middle-income countries (LMICs). We used data from population

BMJ global health2017 Full Text: Link to full Text with Trip Pro

47. Afshinnia F, Rajendiran TM, Karnovsky A, et al. Lipidomic Signature of Progression of Chronic Kidney Disease in the Chronic Renal Insufficiency Cohort. Kidney Int Rep. 2016;1:256–268

Afshinnia F, Rajendiran TM, Karnovsky A, et al. Lipidomic Signature of Progression of Chronic Kidney Disease in the Chronic Renal Insufficiency Cohort. Kidney Int Rep. 2016;1:256–268 29270538 2017 12 22 2468-0249 2 6 2017 Nov Kidney international reports Kidney Int Rep Erratum: Afshinnia F, Rajendiran TM, Karnovsky A, et al. Lipidomic Signature of Progression of Chronic Kidney Disease in the Chronic Renal Insufficiency Cohort. Kidney Int Rep . 2016;1:256-268. 1265 10.1016/j.ekir.2017.09.002 (...) [This corrects the article DOI: 10.1016/j.ekir.2016.08.007.]. eng Published Erratum 2017 09 18 United States Kidney Int Rep 101684752 2468-0249 Kidney Int Rep. 2016 Nov;1(4):256-268 28451650 2017 12 23 6 0 2017 12 23 6 0 2017 12 23 6 0 epublish 29270538 10.1016/j.ekir.2017.09.002 S2468-0249(17)30388-1 PMC5733677

Kidney international reports2017 Full Text: Link to full Text with Trip Pro

48. A policy model of cardiovascular disease in moderate-to-advanced chronic kidney disease

A policy model of cardiovascular disease in moderate-to-advanced chronic kidney disease 28780579 2017 08 06 2017 08 06 1468-201X 2017 Aug 05 Heart (British Cardiac Society) Heart A policy model of cardiovascular disease in moderate-to-advanced chronic kidney disease. heartjnl-2016-310970 10.1136/heartjnl-2016-310970 To present a long-term policy model of cardiovascular disease (CVD) in moderate-to-advanced chronic kidney disease (CKD). A Markov model with transitions between CKD stages (3B, 4 (...) 1355-6037 CKD progression cardiovascular risk chronic kidney disease life expectancy markov model Competing interests: None declared. 2016 11 29 2017 04 19 2017 04 24 2017 8 7 6 0 2017 8 7 6 0 2017 8 7 6 0 aheadofprint 28780579 heartjnl-2016-310970 10.1136/heartjnl-2016-310970

EvidenceUpdates2017

49. Interventions for chronic kidney disease in people with sickle cell disease.

Interventions for chronic kidney disease in people with sickle cell disease. BACKGROUND: Sickle cell disease (SCD) is one of the commonest severe monogenic disorders in the world, due to the inheritance of two abnormal haemoglobin (beta-globin) genes. SCD can cause severe pain, significant end-organ damage, pulmonary complications, and premature death. Kidney disease is a frequent and potentially severe complication in people with SCD.Chronic kidney disease is defined as abnormalities of kidney (...) structure or function, present for more than three months. Sickle cell nephropathy refers to the spectrum of kidney complications in SCD.Glomerular damage is a cause of microalbuminuria and can develop at an early age in children with SCD, and increases in prevalence in adulthood. In people with sickle cell nephropathy, outcomes are poor as a result of the progression to proteinuria and chronic kidney insufficiency. Up to 12% of people who develop sickle cell nephropathy will develop end-stage renal

Cochrane2017

51. Dietary interventions for adults with chronic kidney disease.

Dietary interventions for adults with chronic kidney disease. BACKGROUND: Dietary changes are routinely recommended in people with chronic kidney disease (CKD) on the basis of randomised evidence in the general population and non-randomised studies in CKD that suggest certain healthy eating patterns may prevent cardiovascular events and lower mortality. People who have kidney disease have prioritised dietary modifications as an important treatment uncertainty. OBJECTIVES: This review evaluated (...) the benefits and harms of dietary interventions among adults with CKD including people with end-stage kidney disease (ESKD) treated with dialysis or kidney transplantation. SEARCH METHODS: We searched the Cochrane Kidney and Transplant Specialised Register (up to 31 January 2017) through contact with the Information Specialist using search terms relevant to this review. Studies contained in the Specialised Register are identified through search strategies specifically designed for CENTRAL, MEDLINE

Cochrane2017

52. Etelcalcetide (Parsabiv) - To treat secondary hyperparathyroidism in adult patients with chronic kidney disease undergoing dialysis

Etelcalcetide (Parsabiv) - To treat secondary hyperparathyroidism in adult patients with chronic kidney disease undergoing dialysis Parsabiv (etelcalcetide) Injection U.S. Department of Health and Human Services Search FDA Submit search Parsabiv (etelcalcetide) Injection Parsabiv Company: Amgen, Inc. Application No.: 208325 Approval Date: 02/07/2017 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF

FDA - Drug Approval Package2017

53. Low Urinary Creatinine Excretion Is Associated With Self-Reported Frailty in Patients With Advanced Chronic Kidney Disease

Low Urinary Creatinine Excretion Is Associated With Self-Reported Frailty in Patients With Advanced Chronic Kidney Disease 29142985 2018 11 13 2468-0249 2 4 2017 Jul Kidney international reports Kidney Int Rep Low Urinary Creatinine Excretion Is Associated With Self-Reported Frailty in Patients With Advanced Chronic Kidney Disease. 676-685 10.1016/j.ekir.2017.02.021 Frailty and muscle wasting, a component of frailty, are common in advanced stage chronic kidney disease (CKD). Whether frailty (...) Journal Article 2017 03 10 United States Kidney Int Rep 101684752 2468-0249 chronic kidney disease creatinine frailty muscle 2016 07 15 2017 02 06 2017 02 28 2017 11 17 6 0 2017 11 17 6 0 2017 11 17 6 1 epublish 29142985 10.1016/j.ekir.2017.02.021 S2468-0249(17)30055-4 PMC5678832 J Am Geriatr Soc. 2007 Oct;55(10):1578-84 17908060 Am J Nephrol. 2007;27(3):279-86 17440263 Clin J Am Soc Nephrol. 2016 Apr 7;11(4):626-32 26792529 J Gerontol A Biol Sci Med Sci. 2001 Mar;56(3):M146-56 11253156 Nephrology

Kidney international reports2017 Full Text: Link to full Text with Trip Pro

54. Renocardiovascular Biomarkers: from the Perspective of Managing Chronic Kidney Disease and Cardiovascular Disease

Renocardiovascular Biomarkers: from the Perspective of Managing Chronic Kidney Disease and Cardiovascular Disease 28321399 2018 11 13 2297-055X 4 2017 Frontiers in cardiovascular medicine Front Cardiovasc Med Renocardiovascular Biomarkers: from the Perspective of Managing Chronic Kidney Disease and Cardiovascular Disease. 10 10.3389/fcvm.2017.00010 Mortality among the patients with chronic kidney disease (CKD) and end-stage renal disease (ESRD) remains high because of the very high incidence (...) of cardiovascular disease (CVD) such as coronary artery disease, cardiac hypertrophy, and heart failure. Identifying CVD in patients with CKD/ESRD remains a significant hurdle and the early diagnosis and therapy for CVD is crucial in these patients. Therefore, it is necessary for the better management to identify and utilize cardiovascular (CV) biomarkers in profiling CVD risk and enabling stratification of early mortality. This review summarizes current evidence about renocardiovascular biomarkers: CV

Frontiers in cardiovascular medicine2017 Full Text: Link to full Text with Trip Pro

55. Clinical relevancy and determinants of potential drug–drug interactions in chronic kidney disease patients: results from a retrospective analysis

Clinical relevancy and determinants of potential drug–drug interactions in chronic kidney disease patients: results from a retrospective analysis 29354553 2018 11 13 2230-5254 6 2017 Integrated pharmacy research & practice Integr Pharm Res Pract Clinical relevancy and determinants of potential drug-drug interactions in chronic kidney disease patients: results from a retrospective analysis. 71-77 10.2147/IPRP.S128816 Chronic kidney disease (CKD) alters the pharmacokinetic and pharmacodynamic (...) -5254 CKD DDI Pakistan chronic kidney disease clinical pharmacy drug interaction interactions pharmacist potential drug–drug interactions Disclosure The authors report no conflicts of interest in this work. 2018 1 23 6 0 2018 1 23 6 0 2018 1 23 6 1 epublish 29354553 10.2147/IPRP.S128816 iprp-6-071 PMC5774325 Nephrol Dial Transplant. 2015 Mar;30(3):342-4 24923769 Pharm World Sci. 2010 Dec;32(6):822-8 20963634 PLoS One. 2016 Jul 01;11(7):e0158677 27367594 CMAJ. 2013 Jun 11;185(9):E417-23 23649413

Integrated pharmacy research & practice2017 Full Text: Link to full Text with Trip Pro

56. Is chronic kidney disease an adverse factor in lung cancer clinical outcome? A propensity score matching study

Is chronic kidney disease an adverse factor in lung cancer clinical outcome? A propensity score matching study 28207203 2017 10 30 2018 11 13 1759-7714 8 2 2017 03 Thoracic cancer Thorac Cancer Is chronic kidney disease an adverse factor in lung cancer clinical outcome? A propensity score matching study. 106-113 10.1111/1759-7714.12414 Comorbidity has a great impact on lung cancer survival. Renal function status may affect treatment decisions and drug toxicity. The survival outcome in lung (...) cancer patients with coexisting chronic kidney disease (CKD) has not been fully evaluated. We hypothesized that CKD is an independent risk factor for mortality in patients with lung cancer. A retrospective, propensity-matched study of 434 patients diagnosed between June 2004 and May 2012 was conducted. CKD was defined as estimated glomerular filtration rate <60 mL/minute. Lung cancer and coexisting CKD patients were matched 1:1 to patients with lung cancer without CKD. Age, gender, smoking status

Thoracic cancer2017 Full Text: Link to full Text with Trip Pro

57. Iron (III) isomaltoside 1000 (Diafer) - For the treatment of iron deficiency in adults with chronic kidney disease (CKD) on dialysis

Iron (III) isomaltoside 1000 (Diafer) - For the treatment of iron deficiency in adults with chronic kidney disease (CKD) on dialysis

Scottish Medicines Consortium2017

58. Associations of Protein−Energy Wasting Syndrome Criteria With Body Composition and Mortality in the General and Moderate Chronic Kidney Disease Populations in the United States

Associations of Protein−Energy Wasting Syndrome Criteria With Body Composition and Mortality in the General and Moderate Chronic Kidney Disease Populations in the United States 28840197 2018 11 13 2468-0249 2 3 2017 May Kidney international reports Kidney Int Rep Associations of Protein-Energy Wasting Syndrome Criteria With Body Composition and Mortality in the General and Moderate Chronic Kidney Disease Populations in the United States. 390-399 10.1016/j.ekir.2017.01.002 It is unknown (...) whether the criteria used to define Protein-energy wasting (PEW) syndrome in dialysis patients reflect protein or energy wasting in the general and moderate CKD populations. In 11,834 participants in the 1999-2004 National Health and Nutrition Examination Survey, individual PEW syndrome criteria and the number of PEW syndrome categories were related to lean body and fat masses (measured by dual-energy absorptiometry) using linear regression in the entire cohort and CKD sub-population. Serum chemistry

Kidney international reports2017 Full Text: Link to full Text with Trip Pro

59. Chronic kidney disease: the global challenge.

Chronic kidney disease: the global challenge. The worldwide rise in the number of patients with chronic kidney disease (CKD) and consequent end-stage renal failure necessitating renal replacement therapy is threatening to reach epidemic proportions over the next decade, and only a small number of countries have robust economies able to meet the challenges posed. A change in global approach to CKD from treatment of end-stage renal disease (ESRD) to much more aggressive primary and secondary (...) prevention is therefore imperative. In this Seminar, we examine the epidemiology of CKD worldwide, with emphasis on early detection and prevention, and the feasibility of methods for detection and primary prevention of CKD. We also review the risk factors and markers of progressive CKD. We explore current understanding of the mechanisms underlying renal scarring leading to ESRD to inform on current and future interventions as well as evidence relating to interventions to slow the progression of CKD

Lancet2017

60. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease&mdash

KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease&mdash KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease—mineral and bone disorder (CKD-MBD). | National Guideline Clearinghouse success fail JUN 09 2017 2018 2019 14 Apr 2018 - 12 Jul 2018 COLLECTED BY Organization: Formed in 2009, the Archive Team (not to be confused (...) , read our . Guideline Summary NGC:011233 2017 Jul NEATS Assessment KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease—mineral and bone disorder (CKD-MBD). Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease–mineral and bone disorder (CKD-MBD). Kidney Int Suppl. 2017 Jul;7

National Guideline Clearinghouse (partial archive)2017